Phase I pharmacokinetic, and pharmacodynamic trial of the novel oral notch inhibitor MK-0752 in patients with advanced breast cancer and other solid tumors.

被引：0
|
作者：
Krop, I. E.
Kosh, M.
Fearen, I
Savoie, J.
Dallob, A.
Stone, J.
Winer, E.
Freedman, S. J.
LoRusso, P.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Merck Res Labs, N Wales, PA USA
[3] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S287 / S287
页数：1
相关论文
共 50 条
  • [41] Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial
    Jaremtchuk, AV
    Zabra, JJ
    Ferro, A
    Aman, EF
    Alvarez, R
    Arroyo, G
    Marmissolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S290 - S290
  • [42] A clinical, pharmacodynamic and pharmacokinetic phase I study of SCH 66336 (SCH) an oral inhibitor of the enzyme farnesyl transferase given once daily in patients with solid tumors.
    Awada, A
    Eskens, F
    Piccart, MJ
    Van der Gaast, A
    Bleiberg, H
    Cutler, DL
    Fumoleau, P
    Wanders, J
    Faber, MN
    Verweij, J
    CLINICAL CANCER RESEARCH, 1999, 5 : 3733S - 3733S
  • [43] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors
    Diamond, Jennifer R.
    Bastos, Bruno R.
    Hansen, Ryan J.
    Gustafson, Daniel L.
    Eckhardt, S. Gail
    Kwak, Eunice L.
    Pandya, Shuchi S.
    Fletcher, Graham C.
    Pitts, Todd M.
    Kulikowski, Gillian N.
    Morrow, Mark
    Arnott, Jamie
    Bray, Mark R.
    Sidor, Carolyn
    Messersmith, Wells
    Shapiro, Geoffrey I.
    CLINICAL CANCER RESEARCH, 2011, 17 (04) : 849 - 860
  • [44] Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors
    Brana, Irene
    Gray, Jhanelle Elaine
    Haluska, Paul
    Berger, Raanan
    Golan, Talia
    Jones, Mary Elizabeth
    Gunchenko, Alexandra
    Cheng, Jonathan D.
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.
    Wagner, Andrew J.
    Banerji, Udai
    Mahipal, Amit
    Somaiah, Neeta
    Hirsch, Heather Anne
    Fancourt, Craig
    Levonas, Amy
    Lam, Raymond
    Meister, Amy
    Kemp, Ramon Karmel
    Knox, Clayton
    Rose, Shelonitda
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] A phase I pharmacological and pharmacodynamic study of MK-1775, a Weel tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
    Leijen, S.
    Schellens, J. H.
    Shapiro, G.
    Pavlick, A. C.
    Tibes, R.
    Demuth, T.
    Viscusi, J.
    Cheng, J. D.
    Xu, Y.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors
    Thomas, JP
    Arzoomanian, RZ
    Alberti, D
    Marnocha, R
    Lee, F
    Friedl, A
    Tutsch, K
    Dresen, A
    Geiger, P
    Pluda, J
    Fogler, W
    Schiller, JH
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 223 - 231
  • [48] A phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 given orally to patients with solid tumors.
    Strumberg, D
    Bauer, RJ
    Moeller, JG
    Hilger, R
    Diaz-Carballo, D
    Richly, H
    Kredtke, S
    Beling, C
    Faghih, M
    Heinig, R
    Hedley, D
    Scheulen, ME
    Seeber, S
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3711S - 3711S
  • [49] Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
    Minami, Hironobu
    Kawada, Kenji
    Ebi, Hiromichi
    Kitagawa, Koichi
    Kim, Yon-il
    Araki, Kazuhiro
    Mukai, Hirofumi
    Tahara, Makoto
    Nakajima, Hikaru
    Nakajima, Keiko
    CANCER SCIENCE, 2008, 99 (07): : 1492 - 1498
  • [50] A phase I dose escalation and pharmacodynamic study of AlbuleukinTM administered subcutaneously every other week in patients with advanced solid tumors.
    Syed, SK
    Logan, TF
    Weiss, GR
    Crowder, K
    Rowinsky, E
    Tolcher, A
    Burke, SG
    Grzegorzewski, KJ
    Melder, R
    Fox, RA
    Herpst, JM
    Gallant, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6230S - 6230S
12345